

Objective: (i) present new features of the npde library 2.2 to compute npde (normalised prediction distribution errors) and npd (normalised prediction discrepancies) [1, 2, 3] in R, with methods to handle data below the limit of quantification (BQL) [4], covariate plots [5] and prediction intervals [6]; (ii) propose a new method to re-scale npd/npde while maintaining the shape of the profile.

INTRODUCTION

Model diagnostics

- used for model evaluation and to guide model building
- npd and npde developed for nonlinear mixed effect models [1, 2]
- based on simulations from the models, used to assess model predictability (family of predictive checks)
- implemented in the npde library for R [3, 7] as well as software like Monolix [8] and NONMEM [9]

Recent extensions to npde

- tests and graphs for covariate models [5]
- prediction intervals for graphs [6]
- imputation method to handle data below the quantification limit (BQL) [4]

New feature proposed here: plot using transformed npd/npde preserving the shape of the profile

Computing pd, npd and npde

Model for observation y_{ij}

$$y_{ij} = f(\theta_i, x_{ij}) + g(\theta_i, \gamma, x_{ij})\epsilon_{ij}$$

where:

- subject i ($i = 1, \dots, N$), with n_i observations $\mathbf{y}_i = \{y_{i1}, \dots, y_{in_i}\}$ at times t_{ij}
- f : structural model, common to all subjects
- g : residual error model, eg $g(\theta_i, x_{ij}) = a + b f^c(\theta_i, x_{ij})$
- individual parameters θ_i , often modelled as $\theta_i = h(\mu, \eta_i, z_i)$ (μ : fixed effects; $\eta_i \sim \mathcal{N}(0, \Omega)$: random effects; z_i : known covariates)
- F_{ij} : cumulative distribution function (cdf) of the predictive distribution of Y_{ij} under model M^B obtained using Monte-Carlo simulations
 - K datasets $V^{sim(k)}$ simulated under model M^B using the design of the validation dataset V ($\mathbf{y}_i^{sim(k)}$: vector of simulated observations for the i^{th} subject in the k^{th} simulation)
 - same simulations used to obtain Visual Predictive Check (VPC)
- Prediction discrepancy pd_{ij} for observation y_{ij} defined as $F_{ij}(y_{ij})$
 - pd expected to follow $\mathcal{U}(0, 1)$ under the model
 - inverse transformation to normal distribution yields npd
 - within-subject correlations introduced when multiple observations are available for each subject [1]
- Prediction distribution errors
 - decorrelation using the empirical mean and the empirical variance-covariance matrix over the K simulations for simulated and observed data
 - pde obtained as pd using decorrelated values and transformed to a normal distribution using the inverse of the normal cdf

HANDLING BQL DATA

Methods

- Omitting BQL data from diagnostic graphs may introduce bias [10]
- Instead, compute pd for a censored observation y_{ij}^{cens} by imputation [4]
 - compute probability of being under LOQ, $\Pr(y_{ij}^{cens} \leq \text{LOQ})$, from the predictive distribution
 - set pd_{ij}^{cens} to a value randomly sampled from $\mathcal{U}[0, \Pr(y_{ij}^{cens} \leq \text{LOQ})]$

Computation of npde

- impute censored observations using the simulated distribution F_{ij} (Fig 1) in both original and simulated datasets

- decorrelate using the imputed datasets




Figure 1: Imputing pd_{ij}^{cens} and y_{ij}^{cens}

Illustrative example

- Simulated data based on real data from the COPHAR 3-ANRS 134 multicenter clinical trial [11]
 - M_T : protocol and model based on real data, with $N=50$ subjects
 - HIV viral load decrease during antiretroviral treatment following a bi-exponential model

$$f(\theta_i, x_{ij}) = \log_{10}(P_1 e^{-\lambda_1 x_{ij}} + P_2 e^{-\lambda_2 x_{ij}})$$

- measurements of viral loads 0, 24, 56, 84, 112, 168 days after initiation of treatment
- limit of quantification of 40 to 50 cp/mL (depending on the assay)

simulations settings

- simulation of 1000 datasets under M_T to compute pd and npde
- V_T : 1 dataset simulated with M_T
- V_F : 1 dataset simulated assuming λ_2 divided by 2

Datasets analysed first uncensored, then assuming LOQ=50 cp/mL

Diagnostic graphs with BQL data

Standard diagnostics to detect model misspecification

- scatterplots of npd/npde versus time or predictions
- distribution plots




Figure 2: Scatterplot of npde versus time (top) and empirical cdf (bottom) for simulated dataset V_T : uncensored dataset (left), dataset after censoring using LOQ=50 cp/mL, removing the values below BQL from the plot (middle) or imputing BQL value (right).

Trend in both plots for V_T when omitting BQL data (more visible in scatterplot)

- imputation of BQL data corrects this pattern




Figure 3: Scatterplot of npde versus time for simulated dataset V_F : uncensored dataset (left), dataset after censoring using LOQ=50 cp/mL, removing the values below BQL from the plot (middle) or imputing BQL value (right).

- For V_F , model misspecification more apparent with imputed values
 - however, power to detect misspecification decreases with fraction of BQL data [4]

TRANSFORMED NPD/NPDE

Methods

- Compute mean E_j and standard deviation SD_j of simulated $y_{ij}^{sim(k)}$ for each value x_j of x , and define:

$$tnpde_{ij} = E_j + SD_j npde_{ij}$$

- same equation for npd_{ij}

- Unbalanced design: similar procedure after binning on the X-axis [12]

- All or part of the simulations can be used to obtain a reference profile

Illustration (uncensored dataset)




Figure 4: Scatterplot of npde (left) and npd (middle) versus time with a reference profile as described in methods; VPC (right).

- The addition of the reference plot shows the evolution of the process
 - both npd and npde scatterplots show a pattern similar to VPC
- The distribution of npde accounts for within subject correlations
 - the width of the prediction interval is scaled with the same factor as the npde themselves
- The method adapts easily to datasets including BQL data since the reference profile uses (non censored) simulated data

ASSESSING COVARIATE MODELS

Methods

Two methods proposed [5]:

- test the relationship between npde and a covariate
 - categorical covariates: Wilcoxon test
 - continuous covariates: correlation test
 - scatterplots or whisker plots versus the covariate
- test distribution of npde after splitting by the values of the covariate
 - discretise by quantiles for continuous covariates
- Bonferroni correction for multiple tests

Illustrative example

- Same model and protocol as above, adding a covariate effect
 - simulation of a binary covariate (values: 0/1 with a proportion of 50/50)
 - $V_{T\text{cov}}$: value of λ_2 divided by 2 compared to the population value in subjects with cov=1
 - simulations used to compute npde:
 - * previous simulations assuming no covariate effect (M_T)
 - * simulations with the same covariate model as for $V_{T\text{cov}}$ ($M_{T\text{cov}}$)
- Plots shown for uncensored data




Figure 5: Scatterplot of npde versus time for $V_{T\text{cov}}$ with simulations under M_T (no covariate model, top) and under $M_{T\text{cov}}$ (with covariate model, bottom). On each line: scatterplot regardless of the value of the covariate (left), and for the two levels of the covariate (middle and right).

- Plots stratified by the value of the covariate allow to assess model misspecification level by level
 - model misspecification picked up on plot for covariate level 1 (top right), and on the overall plot (top left)
 - no trend when the same covariate model is used for both simulated and observed data (bottom plots)

CONCLUSION

- Simulation-based diagnostics for non-linear mixed effect models
- Methods to handle BQL data evaluated by a simulation study [4]
 - increased power to detect model misspecification, compared to simply omitting BQL data from the dataset
 - correction for biases in diagnostic plots
 - as expected, decrease in power when the proportion of BQL increases, since the imputation is based on the model
- Transformed npd/npde
 - similar visual interpretation as VPC while retaining the statistical properties of npd/npde
 - naturally handle design heterogeneity without stratifying
 - the reference profile can be computed using all or part of the simulations
- Library npde for R: current version 2.2 available on the CRAN
 - diagnostic graphs: VPC, empirical cumulative distribution functions, probability of being BQL, scatterplots versus X or predictions
 - prediction intervals added to all the plots: very useful to assess model adequacy
 - plots can also be split by covariates

Acknowledgments

The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115156. This work was part of the DDMoRe project but does not necessarily represent the view of all DDMoRe partners.

REFERENCES

[1] F Mentré and S Escolano. Prediction discrepancies for the evaluation of nonlinear mixed-effects models. *J Pharmacokinetic Biopharm*, 33:345–67, 2006.

[2] K Brendel, E Comets, C Laffont, Christian Laveille, and F Mentré. Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. *Pharm Res*, 23:2036–49, 2006.

[3] E Comets, K Brendel, and F Mentré. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. *Comput Meth Prog Biomed*, 90:154–66, 2008.

[4] T H T Nguyen, E Comets, and F Mentré. Prediction discrepancies (pd) for evaluation of models with data under limit of quantification. *J Pharmacokin Pharmacodyn*, 39:499–518, 2012.

[5] K Brendel, E Comets, C Laffont, and F Mentré. Evaluation of different tests based on observations for external model evaluation of population analyses. *J Pharmacokin Pharmacodyn*, 37:49–65, 2010.

[6] E Comets, K Brendel, and F Mentré. Model evaluation in nonlinear mixed effect models, with applications to pharmacokinetics. *J Soc Fran Stat*, 151:106–28, 2010.

[7] R Development Core Team. *R: A language and environment for statistical computing*. Vienna, Austria, 2004.

[8] M Lavielle. *MONOLIX (Modèles Non Linéaires à effets mixtes)*. MONOLIX group, Orsay, France, 2005.

[9] A Boeckmann, L Sheiner, and S Beal. *NONMEM Version 5.1*. University of California, NONMEM Project Group, San Francisco, 1998.

[10] M O Karlsson and R M Savic. Diagnosing model diagnostics. *Clin Pharmacol Ther*, 82:17–20, 2007.

[11] J J Parienti et al. Adherence profiles and therapeutic responses of treatment-naïve HIV-infected patients starting boosted atazanavir-based therapy in the ANRS 134-COPHAR 3 trial. *Antimicrob Agents Chemother*, 57:2265–71, 2013.

[12] M Lavielle and K Bleakley. Automatic data binning for improved visual diagnosis of pharmacometric models. *J Pharmacokin Pharmacodyn*, 38:861–71, 2011.